Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06742957 · ClinicalTrials.gov registry record · Phase 3
Study Comparing Tapinarof Cream 1% To VTAMA ® (Tapinarof Cream 1%) In the Treatment of Plaque Psoriasis
A Phase 3 study, sponsored by Teva Pharmaceuticals USA.
- Completed
- Registry status
- Phase 3
- Development phase
- 560
- Enrollment target
NCT06742957: Completed Phase 3 study, sponsored by Teva Pharmaceuticals USA.
NCT06742957 is a Phase 3 study that has completed, run by Teva Pharmaceuticals USA. The registered enrollment target is 560 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (27% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06742957, a Phase 3 study, has completed, sponsored by Teva Pharmaceuticals USA.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 560 participants
- Enrollment target
Study Summary
To compare the safety and efficacy of the test (Tapinarof Cream 1%), placebo (vehicle cream) and reference VTAMA® (Tapinarof Cream 1%) treatments to demonstrate clinical equivalence in patients with plaque psoriasis.
Primary Outcome
Proportion of patients with treatment success (defined as a Physician Global Assessment (PGA) score of clear (0) or almost clear (1) with a minimum 2-grade improvement from baseline at the end of treatment (Week 12; Study Day 84): Score of (0) Clear: No signs of psoriasis; post-inflammatory hyperpigmentation may be present Score of (1) Almost Clear: No thickening; normal to pink coloration; no to minimal focal scaling Score of (2) Mild: Just detectable to mild thickening; pink to light red co
Interventions
- DRUG Placebo
- DRUG Tapinarof Cream 1%
- DRUG VTAMA®
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 560 participants |
| Start Date | 2024-12-17 |
| Est. Completion | 2025-11-12 |
| Phase | Phase 3 |
What the finished NCT06742957 record still lists
NCT06742957 is an interventional study that assigns participants to a tested intervention. The registered 560 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (27% lower).
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT06742957 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06742957 about?
NCT06742957 is a clinical study titled "Study Comparing Tapinarof Cream 1% To VTAMA ® (Tapinarof Cream 1%) In the Treatment of Plaque Psoriasis". To compare the safety and efficacy of the test (Tapinarof Cream 1%), placebo (vehicle cream) and reference VTAMA® (Tapinarof Cream 1%) treatments to demonstrate clinical equivalence in patients with plaque psoriasis.
What is the current status of trial NCT06742957?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 560 participants. The study started on 2024-12-17. Estimated completion is 2025-11-12.
What interventions are being tested in trial NCT06742957?
The interventions under investigation include: Placebo (DRUG), Tapinarof Cream 1% (DRUG), VTAMA® (DRUG).
Who is sponsoring clinical trial NCT06742957?
This trial is sponsored by Teva Pharmaceuticals USA, which has 83 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06742957's enrollment target sits among peer trials
560 671st of 2000 higher than 1,328 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04661358 · 560 participants · Phase 3
Fenofibrate for Prevention of DR Worsening
- NCT05473871 · 560 participants · NA
Enhancing Capacity in Churches to Implement PA Programs
- NCT06001541 · 560 participants · NA
Web-based Program to Improve Self-management Among Veterans-caregiver Dyads
- NCT06246916 · 560 participants · Phase 3
A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI